Pharmacogenetics in colorectal cancer: A systematic review

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 1079-1099

  Funke, Silvia ^a   Brenner, Hermann ^a   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

5 fluorouracil; Cetuximab; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin; Panitumumab; Pharmacogenetics; Polymorphism; Treatment outcome

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER A1; ALANINE GLYOXYLATE AMINOTRANSFERASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; MONOCLONAL ANTIBODY; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PANITUMUMAB; PLATINUM DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; RALTITREXED; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ACNE; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOPENIA; MONOTHERAPY; MUTATIONAL ANALYSIS; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; PHARMACOGENETICS;

EID: 50149083259     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.1079     Document Type: Review

References (99)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Vesell ES: Advances in pharmacogenetics and pharmacogenomics. J. Clin. Pharmacol. 40(9), 930-938 (2000).
3. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
4. Phillips KA, van Bebber SL: Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov. 4(6), 500-509 (2005).
5. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47(1), 207-214 (1981).
6. Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3), 205-216 (2000).
7. Rothmann KJ, Greenland S: Introduction to categorical statistics. In: Modern Epidemiology. Lippincott-Raven, PA, USA 231-252 (1998)
8. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23(7), 1365-1369 (2005).
9. Lecomte T, Ferraz JM, Zinzindohoue F et al.: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10(17), 5880-5888 (2004).
10. Tournigand C, Andre T, Achille E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
11. Macdonald JS: Toxicity of 5-fluorouracil. Oncology (Williston Park) 13(7 Suppl. 3), 33-34 (1999).
12. Janjan NA, Abbruzzese J, Pazdur R et al.: Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother. Oncol. 51 (2), 153-160 (1999).
13. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46(1), 20-28 (1986).
14. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68(9), 1903-1909 (1991).
15. Kundu NG, Heidelberger C: Cyclopenta(f)isoquinoline derivatives designed to bind specifically to native deoxyribonucleic acid. 3. Interaction of 6-carbamylmethyl-8-methyl-7H- cyclopenta(f)isoquinolin-3(2H)-one with deoxyribonucleic acids and polydeoxyribonucleotides. Biochem. Biophys. Res. Commun. 60(2), 561-568 (1974).
16. Danenberg PV: Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 473(2), 73-92 (1977).
17. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15(1), 368-381 (1997).
18. Zhu AX, Puchalski TA, Stanton VP Jr et al.: Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucavorin chemotherapy in colorectal cancer. Clin. Colorectal Cancer 3(4), 225-234 (2004).
19. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J: Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol. Rep. 17(2), 325-328 (2007).
20. Doroshow JH, Multhauf P, Leong L et al.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J. Clin. Oncol. 8(3), 491-501 (1990).
21. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17 (1), 46-49 (2002).
22. van Cutsem E, Twelves C, Cassidy J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001).
23. Wilson KS, Fitzgerald CA, Barnett JB, Gill S, Khoo KE: Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest. 25(8). 711-714 (2007).
24. Johnston PG, Lenz HJ, Leichman CG et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55(7), 1407-1412 (1995).
25. Lenz HJ, Hayashi K, Salonga D et al.: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4(5), 1243-1250 (1998).
26. Edler D, Glimelius B. Hallstrom, M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20(7), 1721-1728 (2002).
27. Horie N, Aiba H, Oguro, K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
28. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(B4), 3249-3252 (1999).
29. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics. J. 1(1), 65-70 (2001).
30. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19(2), 383-386 (2001).
31. Suh KW, Kim JH, Kim YB, Kim J, Jeong S: Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J. Gastrointest. Surg. 9(3), 336-342 (2005).
32. Dotor E, Cuatrecases M, Martinez-Iniesta M et al.: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J. Clin. Oncol. 24(10), 1603-1611 (2006).
33. Hitre E, Budai B, Adleff V et al.: Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics 15(10), 723-730 (2005).
34. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91(2), 344-354 (2004).
35. Matsui T, Omura K, Kawakami K, Morita S, Sakamoto J: Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol. Rep. 16(5), 1111-1115 (2006).
36. Massacesi C, Terrazino S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5), 1007-1016 (2006).
37. Tsuji T, Hidaka S, Sawai T et al.: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 9(10 Pt 1), 3700-3704 (2003).
38. Ruzzo A, Graziano F, Loupakis F et al.: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J. Clin. Oncol. 25(10), 1247-1254 (2007).
39. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R: Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin. Cancer Res. 12(13), 3928-3934 (2006).
40. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786 (2001).
41. Gordon MA, Gil J, Lu B et al.: Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7(1), 67-88 (2006).
42. Terrazzino S, Agostini M, Pucciarelli S et al.: A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet. Genomics 16(11), 817-824 (2006).
43. Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ et al.: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int. J. Oncol. 28(5), 1303-1310 (2006).
44. Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M: Single nucleotide polymorphism in the 5′-tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer 112(5), 733-737 (2004).
45. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9(5), 1611-1615 (2003).
46. Etienne MC, Formento JL, Chazal M et al.: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14(12), 785-792 (2004).
47. Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol. 13(11), 1379-1385 (2006).
48. Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M: Methylenetetruhydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother. Pharmacol. 57(6), 835-840 (2006).
49. Wisotzkey JD, Toman J, Bell T, Monk JS, Jones D: MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy. Mol. Diagn. 4(2), 95-99 (1999).
50. Zhang W, Press OA, Haimart CA et al.: Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J. Clin. Oncol. 25(24), 3726-3731 (2007).
51. Etienne MC, Chazal M, Laurent-Puig P et al.: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J. Clin. Oncol. 20(12), 2832-2843 (2002).
52. Ahmed IA, Kelly SB, Anderson JJ, Angus B, Challen C, Lunec J: The predictive value of p53 and p33(ING1b) in patients with Dukes C colorectal cancer. Colorectal Dis. (2007).
53. Zhang W, Park DI, Lu B et al.: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res. 11 (2 Pt 1). 600-605 (2005).
54. Kweekel DM, Gelderblom H, Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev. 31(2), 90-105 (2005).
55. Levi F, Metzger G, Massari C, Milano G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38(1), 1-21 (2000).
56. di Francesco AM, Ruggiero A, Riccardi R: Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol. Life Sci. 59(11), 1914-1927 (2002).
57. Grolleau F. Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85(5), 2293-2297 (2001).
58. Wilson RH, Lehky T. Thomas RR, Quinn MG, Floeter MK, Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 20(7), 1767-1774 (2002).
59. Grothey A, Goldberg RM: A review of oxaliplatin and its clinical use in colorectal cancer. Expert. Opin. Pharmacother 5(10), 2159-2170 (2004).
60. Marsh S: Pharmacogenetics of colorectal cancer. Expert. Opin. Parmacother. 6(15), 2607-2616 (2005).
61. London SJ, Yuan JM, Chung FL et al.: Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet 356(9231). 724-729 (2000).
62. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 94(12), 936-942 (2002).
63. Gamelin L, Capitain O, Morel A et al.: Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin. Cancer Res. 13(21), 6359-6368 (2007).
64. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12(10), 3050-3056 (2006).
65. Ishimoto TM, li-Osman F: Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12(7), 543-553 (2002)
66. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24), 8654-8658 (2001).
67. Shirota Y, Stoehlmacher J, Brabender J et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19(23), 4298-4304 (2001).
68. Park DJ, Zhang W, Stoehlmacher J et al.: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol. 1(3), 162-166 (2003).
69. Yu JJ, Lee KB, Mu C et al.: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3), 555-560 (2000).
70. Viguier J, Boige V, Miquel C et al.: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/ 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11 (17), 6212-6217 (2005).
71. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA: Polymorphisms in the DNA repair gene XPD. correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 8(1), 77-81 (1999).
72. Lunn RM, Helzlsouer KJ, Parshad R et al.: XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4), 551-555 (2000).
73. Spitz MR, Wu X, Wang Y et al.: Modulation of nucleoticie excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61(4), 1354-1357 (2001).
74. le Morvan V, Smith D, Laurand A et al.: Determination of ERCC2 Lys751Gln and GSTP1 Ite105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8(12), 1693-1703 (2007).
75. Stoehlmacher J, Ghaderi V, Iobal S et al.: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21 (B4), 3075-3079 (2001).
76. Zhu Y, Spitz MR, Amos CI, Lin J. Schabath MB, Wu X: An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 64(6), 2251-2257 (2004).
77. Zhang W, Stoehlmacher J, Park DJ et al.: Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 5(2), 124-131 (2005).
78. Saitz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
79. Romero RZ, Morales R, Garcia F et al.: Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol. Rep. 16(3), 497-503 (2006).
80. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10(15), 5151-5159 (2004).
81. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25(10), 1157-1164 (1997).
82. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58(3), 468-472 (1998).
83. Iyer L, Ramirez J, Shepard DR et al.: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49(4), 336-341 (2002).
84. Toffoli G, Cecchin E, Corona G et al.: The rote of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24(19), 3061-3068 (2006).
85. Marcuello E, Altes A, Menoyo A, del Rio E, Gomez-Pardo M, Baiget M: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004).
86. Cote JF, Kirzin S, Kramar A et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13(11), 3269-3275 (2007).
87. Ng K, Zhu AX: Targeting the epidermal growth factor receptor in metastatic colorectal. cancer. Crit Rev. Oncol. Hematol. 65(1), 8-20 (2008).
88. Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK: Targeted therapy in rectal cancer. Oncology (Williston Park) 21(9), 1055-1065 (2007).
89. Zhang W, Gordon M, Schultheis AM et al.: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25(24), 3712-3718 (2007).
90. Chung KY, Shia J, Kemeny NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
91. Lievre A, Bachet JB, le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
92. Sartore-Bianchi A, Moroni M, Veronese S et al.: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25(22), 3239-3245 (2007).
93. Moroni M, Veronese S, Benvenuti S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005).
94. Lenz HJ, van CE, Khambata-Ford S et al.: Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan. oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24(30), 4914-4921 (2006).
95. Zhang W, Gordon M, Press OA et al.: Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet. Genomics 16(7), 475-483 (2006).
96. Khambata-Ford S, Garrett CR, Meropol NJ et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007).
97. Rieder MJ, Livingston RJ, Stanaway IB. Nickerson DA: The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. Drug Metab. Rev. 40(2), 241-261 (2008).
98. McCarthy MI, Abecasis GR, Carrion LR et al.: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5). 356-369 (2008).
99. Nebert DW, Zhang G, Vesen ES: From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40(2), 187-224 (2008).